Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...

Eli Lilly announced that its obesity therapy Zepbound delivered superior outcomes versus Novo Nordisk’s Wegovy across five ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

The U.S. and China, after trade talks in Geneva, agreed to cut tariffs on each other by 115 percentage points, for at least 90 days. Treasury Secretary Scott Bessent further added that talks on ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...